Analytical and clinical evaluation of the Bayer ADVIA centaur automated B-type natriuretic peptide assay in patients with heart failure: A multisite study

被引:112
作者
Wu, AHB
Packer, M
Smith, A
Bijou, R
Fink, D
Mair, J
Wallentin, L
Johnson, N
Feldcamp, CS
Haverstick, DM
Ahnadi, CE
Grant, A
Despres, N
Bluestein, B
Ghani, F
机构
[1] Hartford Hosp, Dept Pathol & Lab Med, Hartford, CT 06102 USA
[2] Columbia Presbyterian Med Ctr, Dept Med, New York, NY 10032 USA
[3] Columbia Presbyterian Med Ctr, Dept Pathol, New York, NY 10032 USA
[4] Univ Innsbruck, Dept Internal Med, Div Cardiol, A-6020 Innsbruck, Austria
[5] Univ Uppsala Hosp, Uppsala Clin Res Ctr, Uppsala, Sweden
[6] Univ Uppsala Hosp, Ctr Cardiothorac, Dept Cardiol, Uppsala, Sweden
[7] Henry Ford Hosp, Dept Pathol, Detroit, MI 48202 USA
[8] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA
[9] Ctr Res & Evaluat Diagnost, CRED, Sherbrooke, PQ, Canada
[10] Bayer Healthcare LLC, Div Diagnost, Tarrytown, NY USA
关键词
D O I
10.1373/clinchem.2003.026138
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF). Methods: We evaluated the analytical and clinical performance of the Bayer ADVIA Centaur((R)) BNP assay. Studies included precision, analytical correlation (against the Shionogi ShionoRIA(TM) and Biosite Triage((R)) BNP assays), BNP results for blood collected in plastic tubes containing EDTA vs other collection tubes, high-dose hook effect, detection limits, and interferences. The clinical performance was tested on 2243 blood samples collected from 983 apparently healthy individuals, 538 patients with chronic disease but without HF (renal insufficiency, chronic obstructive pulmonary disease, diabetes, and hypertension), and 722 patients with HF (New York Heart Association classes I-IV). Results: The ADVIA Centaur assay had total imprecision (CV) of 3.4%, 2.9%, and 2.4% at BNP concentrations of 48, 461, and 1768 ng/L, respectively. The Passing-Bablok correlations to the ShionoRIA and Triage were as follows: ADVIA Centaur = 1.11(ShionoRIA) - 1.19 ng/L (r 0.98); ADVIA Centaur = 0.78(Triage) + 5.89 ng/L Q 0.92), respectively. Of the different blood collection tubes, only EDTA plastic tubes (with and without the barrier gel) were acceptable. The lower detection limit was 0.5 ng/L, and there were no interferences from common analytes, other neuropeptides, or unusual antibodies. BNP exhibited different reference intervals according to age and gender. BNP concentrations increased progressively as the severity of HF increased. Conclusions: The ADVIA Centaur is the first commercially available BNP assay for use on an automated immunochemistry platform. This assay has good analytical and clinical performance characteristics for diagnosing HF. (C) 2004 American Association for Clinical Chemistry.
引用
收藏
页码:867 / 873
页数:7
相关论文
共 28 条
[1]  
*AM HEART ASS, 2002, HEART DIS TROK STAT
[2]  
[Anonymous], 1999, EP5A NCCLS
[3]  
*BAYER HEALTHCARE, 2003, ADVIA CENT BNP PACK
[4]   The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma [J].
Belenky, A ;
Smith, A ;
Zhang, B ;
Lin, S ;
Despres, N ;
Wu, AHB ;
Bluestein, BI .
CLINICA CHIMICA ACTA, 2004, 340 (1-2) :163-172
[5]  
*BIOS INC, 2002, TRIAG BNP PACK INS
[6]   Plasma amino-terminal pro-brain natriuretic peptide levels in subjects presenting to the Emergency Department with suspected acute coronary syndrome: possible role in selecting patients for follow up? [J].
Campbell, DJ ;
Munir, V ;
Hennessy, OF ;
Dent, AW .
INTERNAL MEDICINE JOURNAL, 2001, 31 (04) :211-219
[7]  
Del Ry S, 2001, CLIN CHEM LAB MED, V39, P446
[8]  
Fischer Y, 2001, CLIN CHEM, V47, P591
[9]  
Fraser CG, 2001, BIOL VARIATION PRINC, p[46, 67, 104]
[10]  
KONO M, 1993, KAKU IGAKU, V13, P2